Efficacy of RET inhibitors in the management of advanced, RET mutated, pheochromocytoma. Pooled analysis of published cases with the addition of 2 new cases.

Abstract excerpt

PURPOSE: Selective RET inhibitors are approved for treatment of RET-mutant lung and thyroid cancers. RET mutation is a druggable molecular driver of malignant pheochromocytomas/paragangliomas (PPGLs), but few data have been published regarding the efficacy of RET inhibitors in this clinical setting. METHODS: We performed a pooled analysis of RET-mutated PPGLs treated with RET-inhibitors, including both literature...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adrenal Gland Neoplasms
• Share to Pheochromocytoma